Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical surveillance versus rivaroxaban for low-risk isolated subsegmental pulmonary embolism
NL-OMON59060Phase 4Recruiting
- Sponsor
- Insel Gruppe
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in pulmonary embolism (PE) comparing Clinical surveillance / placebo arm with Rivaroxaban anticoagulation arm (2 arms). Started Jul 2021; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON59060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59060.